Prehabilitation with aerobic and resistance exercise to improve fitness and quality of life before CAR-T for older adults with relapsed or refractory multiple myeloma
Prehabilitation in Patients With Multiple Myeloma Receiving CAR-T Therapy
This test sees if an aerobic and resistance exercise program before CAR‑T helps people aged 60 and older with relapsed or refractory multiple myeloma improve physical fitness and quality of life.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 60 Years and up |
| Sex | All |
| Sponsor | Mayo Clinic Academic / other |
| Drugs / interventions | CAR T, CAR-T, chimeric antigen receptor |
| Locations | 1 site (Rochester, Minnesota) |
| Trial ID | NCT07045727 on ClinicalTrials.gov |
What this trial studies
This interventional program enrolls patients aged 60 or older with relapsed or refractory multiple myeloma who are scheduled for CAR‑T therapy and have ECOG performance status under 3. Participants take part in a prehabilitation regimen of supervised aerobic and resistance exercise with exercise counseling and wearable accelerometry to track activity; biospecimens and electronic health record data are also collected. The program requires hematologist and rehabilitation clearance and excludes those with major cardiac contraindications, severe mobility limitations, active infections, or high bleeding/cytopenia risk. Outcomes focus on changes in physical fitness, functional status, and quality of life around the time of CAR‑T infusion.
Who should consider this trial
Good fit: Ideal candidates are people aged 60 or older with relapsed or refractory multiple myeloma who are scheduled for CAR‑T, have ECOG <3, and have clearance from their hematologist to participate in exercise.
Not a fit: Patients under 60, those with other hematologic cancers, significant cardiac or mobility contraindications, active infections, uncontrolled bleeding risks, or severe cytopenias are unlikely to benefit or be eligible.
Why it matters
Potential benefit: If successful, this approach could help older patients maintain or improve physical function and quality of life and better tolerate CAR‑T therapy.
How similar studies have performed: Exercise prehabilitation has shown benefits for fitness and recovery in other cancer and surgical settings, but prehabilitation specifically before CAR‑T in myeloma is relatively novel and not well studied.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Multiple myeloma diagnosis * Females and males ≥ 60 years of age * Eastern Cooperative Oncology Group (ECOG) score of \< 3 * Scheduled for a CAR T therapy transfusion * Apheresis date at least 7 days prior to date of enrollment * Primary hematologist attending physician clearance for exercise Exclusion Criteria: * Females or males \< 60 years of age * Any hematological cancer other than multiple myeloma * Evidence of an absolute contraindication \[e.g., heart insufficiency \> New York Heart Association (NYHA) III or uncertain arrhythmia; uncontrolled hypertension; reduced standing or walking ability for exercise\] * Other comorbidities that preclude participation in the exercise as deemed by physical therapist or physical medicine and rehabilitation (PM\&R) physician * Active infections, active bleeding disorders, and cytopenias at risk for further adverse events deemed by hematologist-oncologist
Where this trial is running
Rochester, Minnesota
- Mayo Clinic in Rochester — Rochester, Minnesota, United States (Recruiting)
Study contacts
- Principal investigator: Nadine H. Abdallah, MD — Mayo Clinic
- Study coordinator: Clinical Trials Referral Office
- Email: mayocliniccancerstudies@mayo.edu
- Phone: 855-776-0015
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.